ReviewArteriosclerosis, thrombosis, and vascular biology2025
Cardiovascular Disease and Cancer: A Dangerous Liaison.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Cancer Across Cardiovascular and Cardiometabolic Conditions: A Systematic Review and Meta-Analysis.European journal of clinical investigation · 2026Pooled it
- Childhood cancer and future cardiometabolic health.npj metabolic health and disease · 2026Review
- Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.European heart journal · 2026Review
- Characterizing primary care in breast cancer survivors after completion of cancer therapy.Cancer causes & control : CCC · 2026Article
- Cardiovascular Phenotypes Across Major Cancer Types: Distribution and Association with All-Cause Mortality in a Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Cardiovascular risk after cancer in patients with ischemic heart disease or peripheral artery disease.Cardio-oncology (London, England) · 2026Article
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Reverse cardio-oncology: neuroendocrine axis activation and cardiovascular-disease-derived factors synergistically remodel the tumor microenvironment.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Acute coronary syndromes across the lifespan of women.NPJ cardiovascular health · 2026Review
- Machine Learning Unveils Dietary Antioxidants as Influential Factors for Diabetes-Cancer Comorbidity: Insights From National Health and Nutrition Examination Survey.Food science & nutrition · 2026Article
- When Cancer Survival Improves, the Heart Becomes the Next Frontier.Korean circulation journal · 2026Article
- Mechanical circulatory support as a bridge to cancer therapy in patients with end stage heart failure: a single center experience.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026Article
- Performance of Traditional Cardiovascular Risk Scores and Objective Optimization in Cancer Survivors.Current oncology (Toronto, Ont.) · 2026Article
- Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.Journal of the American Heart Association · 2026Article
- Management of Implantable Cardiovascular Devices in Patients Undergoing Radiotherapy.Diagnostics (Basel, Switzerland) · 2026Review
- Downregulation of TCF19 and ATAD2 causes endothelial cell cycle arrest at the transition from cardiac hypertrophy to heart failure.Basic research in cardiology · 2025Article
- Review
- Genitourinary system related tumors and coronary atherosclerosis risk: Evidence from a Mendelian randomization study on multi-cohorts.Translational oncology · 2025Article
- Ischemic Injury Drives Nascent Tumor Growth Via Accelerated Hematopoietic Aging.JACC. CardioOncology · 2025Article
- Cancer Development in Atherosclerotic Cardiovascular Disease: JACC: CardioOncology Short-Form Primer.JACC. CardioOncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The field of cardio-oncology has traditionally focused on the impact of cancer and its therapies on cardiovascular health. Mounting clinical and preclinical evidence, however, indicates that the reverse may also be true: cardiovascular disease can itself influence tumor growth and metastasis. Numerous epidemiological studies have reported that individuals with prevalent cardiovascular disease have an increased incidence of cancer. In parallel, studies using preclinical mouse models of myocardial infarction, heart failure, and cardiac remodeling support the notion that cardiovascular disorders accelerate the growth of solid tumors and metastases. These findings have ushered in a new and burgeoning field termed reverse cardio-oncology that investigates the impact of cardiovascular disease pathophysiology on cancer emergence and progression. Recent studies have begun to illuminate the mechanisms driving this relationship, including shared risk factors, reprogramming of immune responses, changes in gene expression, and the release of cardiac factors that result in selective advantages for tumor cells or their local milieu, thus exacerbating cancer pathology. Here, we review the evidence supporting the relationship between cardiovascular disease and cancer, the mechanistic pathways enabling this connection, and the implications of these findings for patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.